Applications in Malignant Brain Tumors

  • Carsten Nieder
  • Mark R. Gilbert
Part of the Medical Radiology book series (MEDRAD)


Overall Survival Epidermal Growth Factor Receptor Brain Metastasis Clin Oncol Malignant Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ameri A, Poisson M, Chauveinc L et al (1997) Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J Neurooncol 32:155–160PubMedGoogle Scholar
  2. Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672PubMedGoogle Scholar
  3. Antonadou D, Paraskevaidis M, Sarris G et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644–3650PubMedGoogle Scholar
  4. Athanassiou H, Synodinou M, Maragoudakis E et al (2005) Randomized phase II study of temozolomide and radiotherapy with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23:2372–2377PubMedGoogle Scholar
  5. Balana C, Lopez-Pousa A, Berrocal A et al (2004) Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. J Neurooncol 70:359–369PubMedGoogle Scholar
  6. Barker FG 2nd, Simmons ML, Chang SM et al (2001) EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:410–418PubMedGoogle Scholar
  7. Belanich M, Pastor M, Randall T et al (1996) Retrospective study of the correlation between DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56:783–788PubMedGoogle Scholar
  8. Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 64:769–774PubMedGoogle Scholar
  9. Bleehen NM, Freedman LS, Stenning SP (1989) A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Int J Radiat Oncol Biol Phys 16:1077–1081PubMedGoogle Scholar
  10. Boiardi A, Silvani A, Milanesi I et al (1992) Efficacy of “8-drugs-in-one-day” combination in treatment of recurrent GBM patients. J Neurooncol 12:153–158PubMedGoogle Scholar
  11. Bossanyi P von, Diete S, Dietzmann K et al (1997) Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol 94:605–611Google Scholar
  12. Bower M, Newlands ES, Bleehen NM et al (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484–488PubMedGoogle Scholar
  13. Brandes AA, Rigon A, Zampieri P et al (1998) Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 82:355–361PubMedGoogle Scholar
  14. Brandes AA, Ermani M, Turazzi S et al (1999) Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17:645–650PubMedGoogle Scholar
  15. Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 22:4779–4786PubMedGoogle Scholar
  16. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012PubMedGoogle Scholar
  17. Buckner JC, Schomberg PJ, McGinnis WL et al (2001) A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92:420–433PubMedGoogle Scholar
  18. Buckner JC, Gesme D Jr, O’Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255PubMedGoogle Scholar
  19. Butowski N, Prados MD, Lamborn KR et al (2005) A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 61:1454–1459PubMedGoogle Scholar
  20. Carrie C, Muracciole X, Gomez F et al (2005) Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 63:711–716PubMedGoogle Scholar
  21. Chakravarti A, Delaney MA, Noll E et al (2001) Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7:2387–2395PubMedGoogle Scholar
  22. Chakravarti A, Loeffler JS, Dyson NJ (2002a) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositol 3-kinase signaling. Cancer Res 62:200–207PubMedGoogle Scholar
  23. Chakravarti A, Chakladar A, Delaney MA et al (2002b) The epidermal receptor growth factor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RASdependent manner. Cancer Res 62:4307–4315PubMedGoogle Scholar
  24. Chamberlain MC, Kormanik P (1999) Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol 43:71–78PubMedGoogle Scholar
  25. Chamberlain MC, Blumenthal DT (2004) Intracranial meningiomas: diagnosis and treatment. Expert Rev Neurother 4:641–648PubMedGoogle Scholar
  26. Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62:1210–1212PubMedGoogle Scholar
  27. Chang SM, Lamborn KR, Malec M et al (2004a) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353–357PubMedGoogle Scholar
  28. Chang SM, Theodosopoulos P, Lamborn K et al (2004b) Temozolomide in the treatment of recurrent malignant glioma. Cancer 100:605–611PubMedGoogle Scholar
  29. Chi SN, Gardner SL, Levy AS et al (2004) Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 22:4881–4887PubMedGoogle Scholar
  30. Cho KH, Hall WA, Gerbi BJ et al (1998) Patient selection criteria for the treatment of brain metastases with stereotactic radiosurgery. J Neurooncol 40:73–86PubMedGoogle Scholar
  31. Choe G, Horvath S, Cloughesy TF et al (2003) Analysis of the phosphatidylinositol 3′-kinase signalling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMedGoogle Scholar
  32. Christodoulou C, Bafaloukos D, Linardou H et al (2005) Temozolomide combined with cisplatin inpatients with brain metastases from solid tumors. J Neurooncol 71:61–65PubMedGoogle Scholar
  33. Clarke K, Basser RL, Underhill C et al (1999) KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. J Clin Oncol 17:2579–2584PubMedGoogle Scholar
  34. Curran WJ, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedGoogle Scholar
  35. Douglas JG, Barker JL, Ellenbogen RG et al (2004) Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 58:1161–1164PubMedGoogle Scholar
  36. Durando X, Lemaire JJ, Tortochaux J et al (2003) High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 31:559–564PubMedGoogle Scholar
  37. Emrich JG, Brady LW, Quang TS et al (2002) Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: 10-year synopsis of a novel treatment. Am J Clin Oncol 25:541–546PubMedGoogle Scholar
  38. Eshleman JS, Carlson BL, Mladek AC et al (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62:7291–7297PubMedGoogle Scholar
  39. Evans AE, Anderson JR, Lefkovitz-Boudreaux IB et al (1996) Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Children’s Cancer Group study. Med Pediat Oncol 27:8–14Google Scholar
  40. Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597PubMedGoogle Scholar
  41. Fisher B, Won M, McDonald D et al (2002) Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53:980–986PubMedGoogle Scholar
  42. Friedman HS, McLendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMedGoogle Scholar
  43. Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–1525PubMedGoogle Scholar
  44. Fukumura D, Xu L, Chen Y et al (2001) Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumours in vivo. Cancer Res 61:6020–6024PubMedGoogle Scholar
  45. Fuller CE, Perry A (2001) Pathology of low-and intermediategrade gliomas. Semin Radiat Oncol 11:95–102PubMedGoogle Scholar
  46. Galanis E, Buckner JC, Burch PA et al (1998) Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol 16:2953–2958PubMedGoogle Scholar
  47. Garvin J, Sposto R, Stanley P et al (2004) Childhood ependymoma: improved survival for patients with incompletely resected tumors with the use of preirradiation chemotherapy (Abstract). Neuro-oncology 6:456Google Scholar
  48. Geng L, Donnelly E, McMahon G et al (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413–2419PubMedGoogle Scholar
  49. Gilbert MR, Friedman HS, Kuttesch JF et al (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncology 4:261–267PubMedGoogle Scholar
  50. Glass J, Silverman CL, Axelrod R et al (1997) Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 20:226–229PubMedGoogle Scholar
  51. Gregor A, Lind M, Newman H et al (1999) Phase II studies of RMP-7 and carboplatin in the treatment of recurrent highgrade glioma. J Neurooncol 44:137–145PubMedGoogle Scholar
  52. Grill J, Le Deley MC, Gambarelli D et al (2001) Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19:1288–1296PubMedGoogle Scholar
  53. Gross MW, Altscher R, Brandtner M et al (2001) Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastoma with topotecan. Strahlenther Onkol 177:656–661PubMedGoogle Scholar
  54. Grossman SA, O’Neill A, Grunnet M et al (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485–1491PubMedGoogle Scholar
  55. Groves MD, Maor MH, Meyers C et al. (1999) A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45:127–135PubMedGoogle Scholar
  56. Grosu AL, Weber WA, Franz M et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519PubMedGoogle Scholar
  57. Guerrieri M, Wong K, Ryan G et al (2004) A randomized phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46:107–111PubMedGoogle Scholar
  58. Haas-Kogan DA, Prados MD, Tihan T et al (2005) Epidermal growth factor receptor, protein kinase B/akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887PubMedGoogle Scholar
  59. Hashimoto N, Murakami M, Takahashi Y et al (2003) Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97:2254–2261PubMedGoogle Scholar
  60. Harris AE, Lee JY, Omalu B (2003) The effect of radiosurgery during management of aggressive meningiomas. Surg Neurol 60:298–305PubMedGoogle Scholar
  61. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedGoogle Scholar
  62. Hildebrand J, De Witte O, Sahmoud T (1998) Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine: a phase II study. J Neurooncol 37:155–160PubMedGoogle Scholar
  63. Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133–3138PubMedGoogle Scholar
  64. Huang H, Okamoto Y, Yokoo H et al (2004) Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 23:6012–6022PubMedGoogle Scholar
  65. Huncharek M, Muscat J (1998) Treatment of recurrent high grade astrocytomas: results of a systematic review of 1415 patients. Anticancer Res 18:1303–1311PubMedGoogle Scholar
  66. Jeremic B, Shibamoto Y, Grujicic D et al (2001) Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. J Neurooncol 51:133–141PubMedGoogle Scholar
  67. Johns TG, Luwor RB, Murone C et al (2003) Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 2003, 15 Dec (Epub ahead of print)Google Scholar
  68. Karim AB, Maat B, Hatlevoll R (1996) A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 2284. Int J Radiat Oncol Biol Phys 36:549–556PubMedGoogle Scholar
  69. Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379PubMedGoogle Scholar
  70. Keles GE, Lamborn KR, Chang SM et al (2004) Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 100:41–46PubMedGoogle Scholar
  71. Kim JH, Kolozsvary A, Rogulski K et al (1998) Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene. Cancer J Sci Am 4:364–369PubMedGoogle Scholar
  72. Klein M, Heimans JJ, Aaronson NK et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet 360:1361–1368PubMedGoogle Scholar
  73. Kocher M, Voges J, Müller RP et al (1998) Linac radiosurgery for patients with a limited number of brain metastases. J Radiosurg 1:9–15Google Scholar
  74. Kocher M, Eich HT, Semrau R et al (2005a) Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther Onkol 181:20–25PubMedGoogle Scholar
  75. Kocher M, Kunze S, Eich HT et al (2005b) Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 181:157–163PubMedGoogle Scholar
  76. LaCroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198PubMedGoogle Scholar
  77. Lammering G, Hewit TH, Valerie K et al (2003) Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int J Radiat Biol 79:561–568PubMedGoogle Scholar
  78. Langer CJ, Ruffer J, Rhodes H et al (2001) Phase II Radiation Therapy Oncology Group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:113–119PubMedGoogle Scholar
  79. Laperriere NJ, Leung PM, McKenzie S et al (1998) Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41:1005–1011PubMedGoogle Scholar
  80. Laws ER, Parney IF, Huang W et al (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467–473PubMedGoogle Scholar
  81. Lebrun C, Fontaine D, Ramaioli A et al (2004) Long-term outcome of oligodendrogliomas. Neurology 62:1783–1787PubMedGoogle Scholar
  82. Lederman G, Wronski M, Arbit E et al (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155–159PubMedGoogle Scholar
  83. Levin VA, Silver P, Hannigan J et al (1990) Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321–324PubMedGoogle Scholar
  84. Levin VA, Yung WK, Bruner J et al (2002) Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 53:58–66PubMedGoogle Scholar
  85. Levin VA, Hess KR, Choucair A et al (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981–990PubMedGoogle Scholar
  86. Loven D, Hardoff R, Sever ZB (2004) Non-resectable slowgrowing meningiomas treated by hydroxyurea. J Neurooncol 67:221–226PubMedGoogle Scholar
  87. Mane JM, Fernandez R, Munoz A et al (2004) Preradiation chemotherapy with VM-26 and CCNU in patients with glioblastoma multiforme. Tumori 90:562–566PubMedGoogle Scholar
  88. Mason WP, Gentili F, Macdonald DR (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341–346PubMedGoogle Scholar
  89. Massimino M, Gandola L, Giangaspero F et al (2004) Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP study. Int J Radiat Oncol Biol Phys 58:1336–1345PubMedGoogle Scholar
  90. McDonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280Google Scholar
  91. McDonald DR, Kiebert G, Prados M et al (2005) Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status and health related quality of life. Cancer Invest 23:138–144Google Scholar
  92. Medical Research Council Brain Tumour Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19:509–518Google Scholar
  93. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 153:2012–2024Google Scholar
  94. Merchant TE, Mulhern RK, Krasin MJ et al (2004) Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22:3156–3162PubMedGoogle Scholar
  95. Milker-Zabel S, Zabel A, Schulz-Ertner D et al (2005) Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 61:809–816PubMedGoogle Scholar
  96. Muracciole X, Romain S, Dufour H et al (2002) PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 52:592–598PubMedGoogle Scholar
  97. Naumann U, Durka S, Weller M (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation. Oncogene 17:1567–1575PubMedGoogle Scholar
  98. Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18:495–499PubMedGoogle Scholar
  99. Nieder C, Grosu AL (2004) Brain toxicity. In: Jeremic B (ed) Advances in radiation oncology in lung cancer. Springer, Berlin Heidelberg New York, pp 383–393Google Scholar
  100. Nieder C, Leicht A, Motaref B et al (1999) Late radiation toxicity after whole-brain radiotherapy: the influence of antiepileptic drugs. Am J Clin Oncol 22:573–579PubMedGoogle Scholar
  101. Nieder C, Petersen S, Petersen C et al (2000a) The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treatment Rev 26:67–73Google Scholar
  102. Nieder C, Grosu AL, Molls M (2000b) A comparison of treatment results for recurrent malignant gliomas. Cancer Treatment Rev 26:397–409Google Scholar
  103. Nieder C, Schlegel J, Andratschke N et al (2003) The role of growth factors in central nervous system tumours. Anticancer Res 23:1681–1686PubMedGoogle Scholar
  104. Nieder C, Andratschke N, Wiedenmann N et al (2004) Radiotherapy for high-grade gliomas: Does altered fractionation improve the outcome? Strahlenther Onkol 180:401–407PubMedGoogle Scholar
  105. Nutt CL, Mani DR, Betensky RA et al (2003) Gene expressionbased classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607PubMedGoogle Scholar
  106. Osoba D, Brada M, Yung WK et al (2000) Health-related quality of life in patients treated with Temozolomide versus Procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481–1491PubMedGoogle Scholar
  107. Pace A, Vidiri A, Galie E et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14:1722–1726PubMedGoogle Scholar
  108. Packer RJ, Goldwein J, Nicholson HS et al (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group study. J Clin Oncol 17:2127–2136PubMedGoogle Scholar
  109. Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases of the brain. N Engl J Med 322:494–500PubMedGoogle Scholar
  110. Patchell RA, Tibbs PA, Regine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain. A randomized trial. J Am Med Assoc 280:1485–1489Google Scholar
  111. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M et al (2005) High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 71:33–38PubMedGoogle Scholar
  112. Peterson K, Harsh G IV, Fisher PG et al (2001) Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma. J Neurooncol 53:27–32PubMedGoogle Scholar
  113. Pirzkall A, Debus J, Lohr F et al (1998) Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16:3563–3569PubMedGoogle Scholar
  114. Poisson M, Pereon Y, Chiras J, Delattre JY (1991) Treatment of recurrent malignant supratentorial gliomas with carboplatin. J Neurooncol 10:139–144PubMedGoogle Scholar
  115. Postmus PE, Haaxma-Reiche H, Smit EF et al (2000) Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy: a phase III study of the EORTC Lung Cancer Cooperative Group. J Clin Oncol 18:3400–3408PubMedGoogle Scholar
  116. Prados MD, Scott C, Curran WJ et al (1999) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17:3389–3395PubMedGoogle Scholar
  117. Prados MD, Wara WM, Sneed PK et al (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49:71–77PubMedGoogle Scholar
  118. Quan AL, Barnett GH, Lee SY et al (2005) Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 63:695–703PubMedGoogle Scholar
  119. Rajkumar SV, Buckner JC, Schomberg PJ et al (1998) Phase I and pharmakokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. Int J Radiat Oncol Biol Phys 42:969–975PubMedGoogle Scholar
  120. Rajkumar SV, Buckner JC, Schomberg PJ et al (1999) Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. Neurosurgery 44:67–73PubMedGoogle Scholar
  121. Rao RD, Krishnan S, Fitch TR et al (2005) Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys 61:380–386PubMedGoogle Scholar
  122. Raymond E, Fabbro M, Boige V et al (2003) Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 14:603–614PubMedGoogle Scholar
  123. Reardon DA, Akabani G, Coleman RE et al (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397PubMedGoogle Scholar
  124. Reardon DA, Quinn JA, Rich JN et al (2004) Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-oncology 6:134–144PubMedGoogle Scholar
  125. Reni M, Brandes AA, Vavassori V et al (2004) A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 100:1221–1229PubMedGoogle Scholar
  126. Roa W, Brasher PMA, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588PubMedGoogle Scholar
  127. Robinet G, Thomas P, Breton JL et al (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12:59–67PubMedGoogle Scholar
  128. Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 31:666–675PubMedGoogle Scholar
  129. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS (1994) Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378–388PubMedGoogle Scholar
  130. Rutkowski S, Bode U, Deinlein F et al (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978–986PubMedGoogle Scholar
  131. Sanson M, Ameri A, Monjour A et al (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer 32A:2229–2235PubMedGoogle Scholar
  132. Schiff D, Shaffrey ME (2003) Role of resection for newly diagnosed malignant gliomas. Expert Rev Anticancer Ther 3:621–630PubMedGoogle Scholar
  133. Schuck A, Muller SB, Kohler A et al (2002) Combined radioche-motherapy with paclitaxel in the treatment of malignant glioma. Strahlenther Onkol 178:486–490PubMedGoogle Scholar
  134. Selker RG, Shapiro WR, Burger P et al (2002) The Brain Tumor Cooperative Group NIH Trial 87-01: a randomised comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:343–353PubMedGoogle Scholar
  135. Shafman TD, Loeffler JS (1999) Novel radiation technologies for malignant gliomas. Curr Opin Oncol 11:147–151PubMedGoogle Scholar
  136. Shai R, Shi T, Kremen TJ et al (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22:4918–4923PubMedGoogle Scholar
  137. Shapiro WR, Green SB, Burger PC et al (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71:1–9PubMedGoogle Scholar
  138. Shaw E, Arusell RM, Scheithauer B et al (2002) A prospective randomized trial of low versus high dose radiation in adults with a supratentorial low grade glioma. J Clin Oncol 20:2267–2276PubMedGoogle Scholar
  139. Shaw E, Seiferheld W, Cairncross JG et al (2004) Radiation therapy alone vs intensive procarbazine, CCNU, vincristine chemotherapy followed by radiation therapy for anaplastic oligodendroglioma and mixed oligoastrocytoma: results of Radiation Therapy Oncology Group (RTOG) — Intergroup protocol 94-02 (Abstract). Int J Radiat Oncol Biol Phys 60(Suppl):S163Google Scholar
  140. Shih HA, Betensky RA, Dorfman MV et al (2005) Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys 63:704–710PubMedGoogle Scholar
  141. Simmons ML, Lamborn KR, Takahashi M et al (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122–1128PubMedGoogle Scholar
  142. Simpson JR, Horton J, Scott CB et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive RTOG clinical trials. Int J Radiat Oncol Biol Phys 26:239–244PubMedGoogle Scholar
  143. Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256PubMedGoogle Scholar
  144. Sneed PK, Lamborn KR, Forstner JM et al (1999) Radiosurgery for brain metastases: Is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 43:549–558PubMedGoogle Scholar
  145. Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60:853–860PubMedGoogle Scholar
  146. Stege EM, Kros JM, de Bruin HG et al (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103:802–809PubMedGoogle Scholar
  147. Stein ME, Kuten A, Drumea K, Goldsher D, Tzuk-Shina Z (1999) Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure. J Surg Oncol 71:167–170PubMedGoogle Scholar
  148. Stemmer-Rachamimov AO, Louis DN (1997) Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 9:230–234PubMedGoogle Scholar
  149. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018PubMedGoogle Scholar
  150. Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedGoogle Scholar
  151. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedGoogle Scholar
  152. Tabori U, Sung L, Hukin J et al (2005) Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management. Cancer 103:1874–1880PubMedGoogle Scholar
  153. Tanaka M, Shibui S, Nomura K et al (2001) Radiotherapy combined with nimustine hydrochloride and etoposide for malignant gliomas: results of a pilot study. Jpn J Clin Oncol 31:246–250PubMedGoogle Scholar
  154. Taylor RE, Bailey CC, Robinson KJ et al (2004) Impact of radiotherapy parameters on outcome in the International Society of Pediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. Int J Radiat Oncol Biol Phys 58:1184–1193PubMedGoogle Scholar
  155. Taylor RE, Bailey CC, Robinson KJ et al (2005) Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41:727–734PubMedGoogle Scholar
  156. Thiessen B, Maguire JA, McNeil K et al (2003) Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64:271–278PubMedGoogle Scholar
  157. Triebels VH, Taphoorn MJ, Brandes AA et al (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63:904–906PubMedGoogle Scholar
  158. Van den Bent MJ, Schellens JH, Vecht CJ et al (1998) Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. Eur J Cancer 34:1570–1574PubMedGoogle Scholar
  159. Van den Bent MJ, Pronk L, Sillevis Smitt PA, Vecht CJ, Eskens FA, Verweij J (1999) Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. J Neurooncol 44:59–64PubMedGoogle Scholar
  160. Van den Bent M, Chinot OL, Cairncross JG (2003) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncology 5:128–138PubMedGoogle Scholar
  161. Van Rijn J, Heimans JJ, van den Berg J et al (2000) Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47:779–784PubMedGoogle Scholar
  162. Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar AK, Kondziolka D, Lunsford LD (2003) Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57:452–464PubMedGoogle Scholar
  163. Verger E, Gil M, Yaya R et al (2005) Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61:185–191PubMedGoogle Scholar
  164. Vos MJ, Uitdehaag BM, Barkhof BM et al (2003) Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 60:826–830PubMedGoogle Scholar
  165. Walker MD, Alexander E, Hunt WE et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333–343PubMedGoogle Scholar
  166. Walker MD, Strike TS, Sheline GE (1979) An analysis of doseeffect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725–1731PubMedGoogle Scholar
  167. Weller M, Streffer J, Wick W et al (2001) Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. Cancer 91:423–427PubMedGoogle Scholar
  168. Weller M, Muller B, Koch R et al (2003) Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21:3276–3284PubMedGoogle Scholar
  169. Westphal M, Hilt DC, Bortey E et al (2003) A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5:79–88PubMedGoogle Scholar
  170. Wolff J, Denecke J, Jurgens H et al (1996) Dexamethasone induces partial resistance to cisplatinum in C6 glioma cells. Anticancer Res 16:805–810PubMedGoogle Scholar
  171. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578PubMedGoogle Scholar
  172. Yung WKA, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762–2771PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Carsten Nieder
    • 1
  • Mark R. Gilbert
    • 2
  1. 1.Department of Radiation OncologyKlinikum Rechts der Isar der Technischen Universität MünchenMunichGermany
  2. 2.Department of Neuro-OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations